SOPHiA GENETICS (SOPH) EBITDA Yield: History & Chart

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T21:18:19.699Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:18:19.699Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -64,056,000
Quote market capitalization: 619,147,048
Total debt · period ending 2026-06-30: 61,827,000
Cash · period ending 2026-06-30: 107,665,000

FMP input reference: bc1f4c18f19876ab16fbc38bb33c2f59d02ebf5b777874ee4386cd5e587f8fe3

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

SOPH EBITDA Yield Metrics

EBITDA YIELD

N/A

SOPH Competitors' EBITDA Yield

SOPH

SOPHiA GENETICS S.A.

Current

Market Cap

$619.15M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CLYM

Climb Bio, Inc.

vs SOPH

Market Cap

$611.57M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OABI

OmniAb, Inc.

vs SOPH

Market Cap

$630.63M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PRME

Prime Medicine, Inc.

vs SOPH

Market Cap

$632.16M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ZVRA

Zevra Therapeutics, Inc.

vs SOPH

Market Cap

$634.30M

EBITDA Yield

8.26%

TTM Avg

7.14%

3Y Avg

7.14%

5Y Avg

6.31%

AURA

Aura Biosciences, Inc.

vs SOPH

Market Cap

$638.20M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IRWD

Ironwood Pharmaceuticals, Inc.

vs SOPH

Market Cap

$597.55M

EBITDA Yield

25.99%

TTM Avg

14.91%

3Y Avg

12.56%

5Y Avg

12.68%

ANGO

AngioDynamics, Inc.

vs SOPH

Market Cap

$596.01M

EBITDA Yield

N/A

TTM Avg

11.92%

3Y Avg

8.30%

5Y Avg

4.40%

FLGT

Fulgent Genetics, Inc.

vs SOPH

Market Cap

$584.48M

EBITDA Yield

N/A

TTM Avg

41.20%

3Y Avg

25.05%

5Y Avg

21.67%

KIDS

OrthoPediatrics Corp.

vs SOPH

Market Cap

$583.31M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
SOPHiA GENETICS S.A. (SOPH)	$619.15M	N/A	N/A	N/A	N/A
Climb Bio, Inc. (CLYM)vs ›	$611.57M	N/A	N/A	N/A	N/A
OmniAb, Inc. (OABI)vs ›	$630.63M	N/A	N/A	N/A	N/A
Prime Medicine, Inc. (PRME)vs ›	$632.16M	N/A	N/A	N/A	N/A
Zevra Therapeutics, Inc. (ZVRA)vs ›	$634.30M	8.26%	7.14%	7.14%	6.31%
Aura Biosciences, Inc. (AURA)vs ›	$638.20M	N/A	N/A	N/A	N/A
Ironwood Pharmaceuticals, Inc. (IRWD)vs ›	$597.55M	25.99%	14.91%	12.56%	12.68%
AngioDynamics, Inc. (ANGO)vs ›	$596.01M	N/A	11.92%	8.30%	4.40%
Fulgent Genetics, Inc. (FLGT)vs ›	$584.48M	N/A	41.20%	25.05%	21.67%
OrthoPediatrics Corp. (KIDS)vs ›	$583.31M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

SOPH EBITDA Yield Metrics

SOPH Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics